RxDoctor Payments Data

Edwin Silva Zapata, MD

Family Medicine · High Point, NCNPI 1760896518

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 16 payments — averaging $69.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$402
  • GSK$243
  • Lilly USA, LLC$125
  • Dexcom, Inc.$115
  • Intuitive Surgical$73
  • Novartis$65
  • plus $85 from 2 others

What the payments were for

  • Food & beverage$1,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$402
GSK2$243
Lilly USA, LLC1$125
Dexcom, Inc.1$115
Intuitive Surgical1$73
Novartis4$65
Abbott1$63
Nevro Corp.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,108 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$65,757
Medicare patients
155
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$101,309
OzempicSemaglutide74$100,434
FarxigaDapagliflozin Propanediol73$89,720
EliquisApixaban62$75,419
MounjaroTirzepatide28$35,794
JanuviaSitagliptin Phosphate24$24,939
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$12,213
Tresiba Flextouch U-200Insulin Degludec22$12,045
Janumet XrSitagliptin Phos/Metformin Hcl12$9,849
LivaloPitavastatin Calcium12$8,968
Breo ElliptaFluticasone/Vilanterol16$8,217
Rosuvastatin Calcium588$6,712
JanumetSitagliptin Phos/Metformin Hcl12$6,696
XareltoRivaroxaban11$5,715
PaxlovidNirmatrelvir/Ritonavir15$5,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$402$100,43474 claims
Lilly USA, LLCMounjaro$125$35,79428 claims
GSKBreo Ellipta$243$8,21716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in High Point

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →